Bio Vitos Pharma
Iron fullstop a global health challenge - Our revolutionary solution.
The Problem & The Solution
A global health challenge. A revolutionary solution.
Over 2 billion people suffer from iron deficiency. Despite this, up to 60% discontinue their treatment due to severe gastrointestinal side effects from traditional preparations.
Bio Vito’s Innovation: Our unique iron succinate is the only iron compound in the world with documented zero significant side effects. We offer a treatment that patients can actually and want to complete.
Three global billion-dollar markets
Produkt 1
FE-MININ™
Target group
Women and athletes.
Description
Addresses the world’s most common nutritional deficiency with a focus on energy, recovery and quality of life.
Produkt 2
MAXFERMAN™
Target group
Men 40+.
Description
Targeted treatment for the growing group of men experiencing sudden physical and mental decline.
Produkt 3
SUCCIFER®
Target group
Heart failure patients.
Description
The world’s first potential oral treatment that could replace costly and risky iron injections in hospitals.
Momentum & Milestones
The path to market approval and global expansion 2026-2027
Milestone 1
Completion of clinical studies for FE-MININ™ and MAXFERMAN™ .
Milestone 2
Scientific publications and submission of three EFSA applications.
Milestone 3
Expected EFSA approval and immediate availability to 27 EU countries.
Milestone 4
Planned listing on the American stock exchange (IPO).
A unique investment opportunity
Patented Security
Patent protection in 26 European countries for the treatment of heart failure.
Scalable Business Model.
Forecasted turnover of €316M by 2030 with strong margins.